Last edition
News about "High-Risk Smoldering Multiple Myeloma"
FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.
High-Risk Smoldering Multiple Myeloma | 11/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members